ALGENTECH
Algentech Granted US Patent For A Key Genome Editing Technology
Algentech's invention optimizes the cellular process known as homologous recombination. In order to precisely insert or modify a genetic sequence, existing technologies use nucleases that introduce specific breaks in the target DNA and then rely on the cellular machinery to complete the editing process.
